<code id='77E21E510F'></code><style id='77E21E510F'></style>
    • <acronym id='77E21E510F'></acronym>
      <center id='77E21E510F'><center id='77E21E510F'><tfoot id='77E21E510F'></tfoot></center><abbr id='77E21E510F'><dir id='77E21E510F'><tfoot id='77E21E510F'></tfoot><noframes id='77E21E510F'>

    • <optgroup id='77E21E510F'><strike id='77E21E510F'><sup id='77E21E510F'></sup></strike><code id='77E21E510F'></code></optgroup>
        1. <b id='77E21E510F'><label id='77E21E510F'><select id='77E21E510F'><dt id='77E21E510F'><span id='77E21E510F'></span></dt></select></label></b><u id='77E21E510F'></u>
          <i id='77E21E510F'><strike id='77E21E510F'><tt id='77E21E510F'><pre id='77E21E510F'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:77
          Illustration of a road with a chasm in the middle, indicating the end of a deal or a problem with a deal
          Adobe

          A deal is never really done until it’s done.

          On Tuesday, two different proposed insurance plan acquisitions on different sides of the country called it quits — one of them for the second time.

          advertisement

          California-based Medicare Advantage insurer SCAN Group has been trying to buy CareOregon, an insurer offering coverage to half a million people in Oregon’s state health plan, since January 2023. National insurer Elevance has also been trying to buy Blue Cross and Blue Shield of Louisiana since last January. The on-again, off-again purchase was paused in September 2023 because of state regulators’ concerns, but was resubmitted with a slightly different plan in December.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Gene editing the human germline: What are the risks?
          Gene editing the human germline: What are the risks?

          Germlineeditingcanbeusedtorepairadefectivegeneinaspermcell.APStockGeneeditingholdsgreatpromisefortre

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          For AI in health care standards, federal regulators join with industry group

          AdobeAtfirstglance,theCoalitionforHealthAIlookslikeanytechnologylobbyinggroup.Itsmembership—includin